Stefan Barth

The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice

V. Diehl, M. Zeitz, S. Barth, 2002, International Journal of Colorectal Disease.

Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells.

S. Barth, T. Keler, R. Graziano, 2001, Journal of immunological methods.

Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.

V. Diehl, S. Barth, R. Schnell, 2000, Blood.

A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.

V. Diehl, H. Tesch, M. Hansmann, 1997, Blood.

Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning

J. Arends, R. Roovers, H. Hoogenboom, 2000, British Journal of Cancer.

Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions

S. Barth, E. Galinski, A. Engert, 2000, Applied and Environmental Microbiology.